Adaptive Biotechnologies Corp

NASDAQ:ADPTUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Contact Information

Headquarters

1165 Eastlake Ave ESEATTLE, WA, United States 98109

Phone

206-659-0067

Fax

206-659-0667

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Chad Robins

President, Chief Operating Officer

Julie Rubinstein

Co-Founder, Chief Scientific Officer

Harlan Robins

Chief Financial Officer

Kyle Piskel

Chief People Officer

Francis Lo